Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion

Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $26.00 price target.

John Newman’s rating is based on several key factors that suggest a positive outlook for Y-Mabs Therapeutics. Despite a decline in DANYELZA’s revenue in the first quarter of 2025 due to increased competition, the company’s full-year revenue guidance remains unchanged, indicating a potential rebound in the latter half of the year. This optimism is supported by the inclusion of DANYELZA in the NCCN guidelines for treating high-risk neuroblastoma, which is expected to enhance brand recognition and physician adoption.
Moreover, the anticipated release of Phase 1 data for GD2-SADA on May 28th could further bolster the company’s prospects. This data will focus on pharmacokinetics and dosing, along with new technology that promises improved affinity and longer residence time. These developments, coupled with strategic business realignment efforts, underpin Newman’s confidence in Y-Mabs Therapeutics, leading to a maintained Buy rating and a price target of $26.

In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.

YMAB’s price has also changed dramatically for the past six months – from $13.180 to $4.160, which is a -68.44% drop .